NCT07260760Not yet recruiting
Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 20 Nov 2025
- Start date
- 20 Jan 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Qianfoshan Hospital
- Diseases
- Stroke
- NCT number
- NCT07260760
What you commit to
- Study type: Observational
- Planned participants: 600
- From 20 Jan 2026 to the primary completion date, 31 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- 1: A head CT or MRI scan indicates the presence of intracranial hemorrhagic disease
- 2: Patients with cerebral embolism or suspected cerebral embolism who also have severe atrioventricular block, atrial fibrillation, myocardial infarction, valvular heart disease, infective endocarditis, or a heart rate below 50 beats per minute
- 3: Abnormal liver function (ALT or AST transaminase levels exceeding the upper limit of normal), abnormal kidney function (creatinine levels exceeding the upper limit of normal), or individuals with other severe systemic diseases, etc
- 4: Allergy to the test drug
Who the study is looking for
- 1: Age≥18
- 2: Acute ischemic stroke in the anterior circulation occurring within 48 hours
- 3: Baseline NIHSS score of 1-15 points (mild stroke: baseline NIHSS score of 1-5 points; moderate stroke: baseline NIHSS score of 6-15 points)
- 4: Pre-onset mRS score≤1
- 5: Use of Edaravone (injection or tablets)
- 6: Exclude intracranial hemorrhage
- 7: Sign the informed consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.